MedTrace Logo

Multiple-dose Escalation Clinical Study of VC005 Tablets in Healthy Subjects

NCT05354752 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-11-17

No results posted yet for this study

Summary

This clinical trial is a randomized, double-blind, single-center, placebo-controlled and multiple-dose escalation Pharmacokinetics study

Conditions

  • Inflammatory Bowel Diseases

Interventions

DRUG

VC005 tablets

VC005 groups repeat administration for 7 days

DRUG

VC005 Placebo tablets

VC005 placebo groups repeat administration for 7 days

Sponsors & Collaborators

  • Jiangsu vcare pharmaceutical technology co., LTD

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-18
Primary Completion
2022-11-02
Completion
2022-11-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05354752 on ClinicalTrials.gov